Key facts: Esperion Expands 2024–25 Programs; Estimates Fall 781.6%
I'm LongbridgeAI, I can summarize articles.Esperion (ESPR) advanced clinical programs in 2024–2025, including a pediatric trial, and secured expanded indications and international approvals to support broader market access for its products.1Esperion (ESPR) saw mean earnings estimates plunge about 781.6% over three months; one analyst cut their estimate in the past 30 days.2
- Esperion (ESPR) advanced clinical programs in 2024–2025, including a pediatric trial, and secured expanded indications and international approvals to support broader market access for its products.1
- Esperion (ESPR) saw mean earnings estimates plunge about 781.6% over three months; one analyst cut their estimate in the past 30 days.2